Syon Capital LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY)

Syon Capital LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,788 shares of the company’s stock after buying an additional 1,274 shares during the period. Syon Capital LLC’s holdings in Eli Lilly and Company were worth $6,289,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Kirr Marbach & Co. LLC IN increased its position in shares of Eli Lilly and Company by 1.5% during the third quarter. Kirr Marbach & Co. LLC IN now owns 5,782 shares of the company’s stock worth $3,105,000 after purchasing an additional 88 shares in the last quarter. Fifth Third Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 113.6% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 6,195 shares of the company’s stock valued at $3,328,000 after acquiring an additional 3,295 shares during the period. 1900 Wealth Management LLC increased its position in shares of Eli Lilly and Company by 28.3% in the 3rd quarter. 1900 Wealth Management LLC now owns 1,028 shares of the company’s stock valued at $552,000 after acquiring an additional 227 shares during the period. Park Place Capital Corp increased its position in shares of Eli Lilly and Company by 19.5% in the 3rd quarter. Park Place Capital Corp now owns 3,041 shares of the company’s stock valued at $1,633,000 after acquiring an additional 496 shares during the period. Finally, Eastern Bank increased its position in shares of Eli Lilly and Company by 155.9% in the 3rd quarter. Eastern Bank now owns 30,283 shares of the company’s stock valued at $16,266,000 after acquiring an additional 18,449 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LLY shares. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Trading Up 1.2 %

NYSE LLY traded up $8.64 during mid-day trading on Friday, reaching $733.51. 1,998,848 shares of the stock were exchanged, compared to its average volume of 3,016,344. Eli Lilly and Company has a 1-year low of $380.77 and a 1-year high of $800.78. The business’s fifty day simple moving average is $762.75 and its 200 day simple moving average is $664.94. The stock has a market capitalization of $696.95 billion, a PE ratio of 126.80, a PEG ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter last year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.